STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags
Eason Technology (NYSE: DXF) has received a notification from NYSE Regulation due to failing to file its 2024 Form 20-F by the May 15, 2025 deadline. The company now enters a six-month Initial Cure Period until November 15, 2025 to resolve the filing delinquency. If unsuccessful, NYSE American may grant an Additional Cure Period until May 15, 2026. Failure to comply could result in suspension and delisting procedures. The delay stems from complications in completing financial statements for the period ended December 31, 2024. While the company's ADSs continue trading on NYSE American during the cure period, there's no guarantee of regaining full compliance with Exchange listing standards.
Loading...
Loading translation...

Positive

  • None.

Negative

  • Failed to file Form 20-F by the required deadline, risking NYSE American listing status
  • Delay in completing 2024 financial statements indicates potential internal control or accounting issues
  • Risk of stock suspension and delisting if compliance is not achieved within cure periods

Insights

Eason Technology faces NYSE compliance issues after missing 20-F filing deadline, risking potential delisting if not resolved by November.

The notification from NYSE Regulation represents a significant regulatory concern for Eason Technology Limited. The company has failed to file its Form 20-F annual report for the period ended December 31, 2024, which was due by May 15, 2025. This places the company in non-compliance with NYSE American's continued listing standards.

The exchange has initiated a structured remediation process with defined timelines. Eason Technology now has an Initial Cure Period until November 15, 2025 (six months) to file the delinquent report. If unsuccessful, NYSE may grant an Additional Cure Period extending to May 15, 2026, though this is discretionary based on the company's specific circumstances.

Particularly concerning is the company's explanation that the delay stems from difficulties completing its financial statements for the period ended December 31, 2024. While the company states it's making efforts to file as soon as possible, it notably includes language that there's "no assurance" it will ultimately regain compliance.

For investors, the immediate impact is limited as the ADSs will continue trading during the cure period. However, the underlying issue - inability to produce timely financial statements - raises potential red flags about financial controls, accounting practices, or possibly more serious issues that prevented timely reporting. Delayed financial reporting often precedes more significant negative disclosures once the financials are eventually filed.

Foreign issuers like Eason Technology face additional scrutiny in such situations, as the inability to file the 20-F can indicate either operational issues or potentially deeper governance concerns that warrant investor attention.

HONG KONG, May 23, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason Technology" or the "Company") (NYSE: DXF) today announced that it received a notice from NYSE Regulation indicating that the Company is not in compliance with the continued listing standards of NYSE American LLC ("NYSE American" or the "Exchange"). The Company failed to timely file its Form 20-F for the period ended December 31, 2024 (the "2024 Form 20-F") by the filing due date of May 15, 2025 (the "Filing Delinquency"). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide.

NYSE Regulation notified the Company that NYSE American will closely monitor the status of the Company's 2024 Form 20-F and any subsequent delayed filings for a six-month period from the date of the Filing Delinquency until November 15, 2025 (the "Initial Cure Period"). If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in its sole discretion, allow the Company's securities to be traded for up to an additional six-month period May 15, 2026 (the "Additional Cure Period") depending on the Company's specific circumstances. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 hereof. If the Exchange determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file the 2024 Form 20-F and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence.

As disclosed in the Form 12b-25 filed by the Company on April 30, 2025, the Company was unable, without unreasonable effort or expense, to file its 2024 Form 20-F as a result of a delay in completing its financial statements for the period ended December 31, 2024. The Company was not able to make the required filing by May 15, 2025. The Company is making all efforts to file the 2024 Form 20-F as soon as possible and within the Initial Cure Period. However, there can be no assurance that the Company will ultimately regain compliance with all applicable Exchange listing standards.

This delinquency notice has no immediate impact on the listing of the Company's ADSs, which will continue to be listed and traded on the NYSE American during the cure period subject to continued compliance with the other listing requirements of the NYSE American.

About Eason Technology Limited

Eason Technology Limited is a company engaged in real estate operation management and investment and digital technology security business in Hong Kong, China.

Safe Harbor Statement

Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

Cision View original content:https://www.prnewswire.com/news-releases/eason-technology-limited-receives-notification-from-nyse-regarding-delayed-form-20-f-filing-302464087.html

SOURCE Eason Technology Limited

FAQ

Why did Eason Technology (DXF) receive a notice from NYSE American?

Eason Technology received the notice because it failed to timely file its Form 20-F for the period ended December 31, 2024, by the May 15, 2025 deadline.

What is the deadline for DXF to resolve its NYSE listing compliance issues?

DXF has an Initial Cure Period until November 15, 2025, with a possible Additional Cure Period until May 15, 2026, to resolve the filing delinquency.

Will DXF stock continue trading on NYSE American after the notification?

Yes, DXF's ADSs will continue trading on NYSE American during the cure period, subject to compliance with other listing requirements.

What happens if DXF fails to file its Form 20-F within the cure period?

If DXF fails to file within the cure periods, NYSE American may initiate suspension and delisting procedures for the stock.

Why was Eason Technology unable to file its 2024 Form 20-F on time?

The company cited delays in completing its financial statements for the period ended December 31, 2024, without being able to do so without unreasonable effort or expense.
Eason Technology

NYSE:DXF

DXF Rankings

DXF Latest News

DXF Latest SEC Filings

DXF Stock Data

3.30M
1.38M
17.43%
12.25%
Credit Services
Financial Services
Link
China
Wuhan